## **ARTICLE IN PRESS**

Journal of Clinical Neuroscience xxx (2017) xxx-xxx



Contents lists available at ScienceDirect

# Journal of Clinical Neuroscience



journal homepage: www.elsevier.com/locate/jocn

### **Review** article

# Outcomes following polyetheretherketone (PEEK) cranioplasty: Systematic review and meta-analysis

Maria Punchak<sup>a</sup>, Lawrance K. Chung<sup>a</sup>, Carlito Lagman<sup>a</sup>, Timothy T. Bui<sup>a</sup>, Jorge Lazareff<sup>a</sup>, Kameron Rezzadeh<sup>b</sup>, Reza Jarrahy<sup>b</sup>, Isaac Yang<sup>a,\*</sup>

<sup>a</sup> Department of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA <sup>b</sup> Department of Plastic Surgery, University of California, Los Angeles, Los Angeles, CA, USA

#### ARTICLE INFO

Article history: Received 28 December 2016 Accepted 6 March 2017 Available online xxxx

*Keywords:* Cranioplasty Meta-analysis Outcomes

#### ABSTRACT

Polyetheretherketone (PEEK) has been used in cranioplasty since the early 2000s. However, there remains limited data that compares its long-term complication rate to autologous grafts and titanium mesh implants. To compare complication and implant failure rates after PEEK, autologous and titanium mesh cranioplasties, the authors of this study conducted a systematic review using the PubMed database. Studies that contained outcome data on complication rates of PEEK cranioplasty patients and studies that compared outcomes of patients who underwent PEEK cranioplasties versus other materials were included in the meta-analysis. Pooled odds ratios using the Mantel-Haenszel method were used for analysis. Fifteen articles, comprised of 183 PEEK cranioplasty patients were included. Of these patients, 15.3% developed post-operative complications and 8.7% experienced implant failure requiring reoperation. Patients who underwent cranioplasties with PEEK implants had 0.130 times the odds of developing post-operative complications (P = 0.065) and 0.574 times the odds of implant failure compared to patients with autologous bone graft cranioplasties (P = 0.629). Patients who had undergone PEEK cranioplasties had 0.127 times the odds of developing post-op complications (P = 0.360) and 0.170 times the odds of implant failure compared to individuals who had undergone titanium mesh cranioplasties (P = 0.168). The analysis was severely limited by the paucity in literature. However, there was a trend toward lower post-operative complication rates following PEEK cranioplasty versus autologous grafts, and lower implant failure rates with PEEK versus titanium mesh implants.

© 2017 Published by Elsevier Ltd.

#### 1. Introduction

Acquired defects of the skull represent a reconstructive challenge for surgeons involved in the care of patients with full thickness cranial bone loss due to cancer, trauma, infection, or other etiologies. Early reports of cranioplasty techniques date back to the 1600s, and during the past half century this procedure has become commonplace in neurosurgical practice [1]. Autologous bone grafts of calvarial, costal, or iliac source have traditionally served as the "gold standard" in cranial vault reconstruction [2]. Bone grafts are associated with low costs and minimal risk profiles, but their use is limited by a finite amount of available donor graft material, donor site morbidity, difficulty in shaping the graft,

\* Corresponding author at: Department of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Suite 562, 5th Floor Wasserman Building, Los Angeles, CA 90095-6901, USA, Fax: +1 (310) 825 9385.

E-mail address: iyang@mednet.ucla.edu (I. Yang).

http://dx.doi.org/10.1016/j.jocn.2017.03.028 0967-5868/© 2017 Published by Elsevier Ltd. increased operative times and perioperative risks, as well as the risks of infection, fragmentation and resorption [3].

Currently, reconstructive surgeons have an array of alloplastic materials at their disposal that serve as alternatives to autologous bone. Poly(methyl methacrylate) (PMMA) was one of the early artificial materials used to fill cranial defects. It is durable, malleable, and relatively inexpensive, but polymerizes via an exothermic reaction that can be harmful to overlying soft tissues [4]. Other clinically established bone "cements" include hydroxyapatite and calcium phosphate, each with its own set of advantages and disadvantages [5,6]. More recently, titanium mesh has become a popular material for use in cranioplasty. It is easy to handle, can be readily shaped to fit the specific contour of any given defect-either by hand or via computer-assisted design/computer-assisted manufacture (CAD/CAM) technology-and has an acceptable cost. The use of titanium alloy, however, is associated with infection, implant exposure, the generation of artifact in the setting of computed tomography (CT) or magnetic resonance imaging (MRI), and the

potential for poor long-term adaptability with overlying soft tissue coverage [7–9].

Over the past several years, polyetheretherketone (PEEK) has gained popularity in the setting of cranial vault reconstruction [10]. PEEK has many positive qualities-it is chemically inert, the polymer maintains structural stability at temperature greater than 300 degrees Celsius, implants can be sterilized by both steam and gamma irradiation, and it has strength and elastic properties that are similar in specification to cortical bone [11–13]. It is also well suited to CAD/CAM surgical planning, rendering it adaptable to a wide array of cranial defects. Unlike titanium, it is radiolucent and does not produce significant artifacts in imaging studies [11].

Despite the increasing popularity of PEEK, there is a paucity of published data on outcomes in patients who have undergone PEEK cranioplasty. Moreover, little is known regarding how PEEK performs relative to other materials that are popularly used for cranioplasties. The authors of this study addressed this gap in knowledge by performing a meta-analysis to compare PEEK, autologous bone and titanium mesh cranioplasty outcomes. Primary outcomes of interest were implant infection, complication and failure rates (defined as implant infection or bone flap resorption requiring removal and/or replacement of implanted material) [14].

#### 2. Methods

#### 2.1. Search strategy and article selection

Independent searches of the currently published literature were performed by the first (M.P.) and second (L.K.C.) authors. PubMed was gueried using search terms "polyetheretherketone," "PEEK," "cranioplasty," "cranial reconstruction," and "calvarial reconstruction." Titles were screened and irrelevant articles were excluded. Full-text English articles describing outcomes of PEEK cranioplasty and articles comparing outcomes of PEEK versus autologous bone or titanium mesh cranioplasties (between 2007 and 2015) were included in the meta-analysis. Case series, comparative retrospective analyses, prospective cohort studies and case reports were included. Non-English text, abstract only, articles failing to stratify outcomes based on cranioplasty technique, or previously published patient data were excluded [12,13,15–21]. The authors did not contact authors of excluded studies for further information. Bibliographies of all peer-reviewed papers generated by this query were further reviewed to identify additional articles. No registered clinical trials nor published systematic reviews/meta-analyses reporting on the use of PEEK implants in cranioplasty were identified.

#### 2.2. Data extraction

Study sample size, patient demographics, follow-up duration indications for craniectomy, location of defect and defect size, duration of surgery and hospitalization, rates and types of complications, and implant failure rates were extracted, independently tabulated and verified by the first (M.P.) and second (L.K.C.) authors. Implant failure was defined as implant infection or bone flap resorption requiring removal and/or replacement of implanted material [14].

#### 2.3. Statistical analysis


Statistical analysis was performed using Stata 12.1 (Stata Corp, College Station, TX, USA). The meta-analysis compared complication, failure and infection rates of PEEK versus autologous graft cranioplasties and PEEK versus titanium mesh cranioplasties using the Mantel–Haenszel method to pool data. Autologous grafts were defined as either patient-donated bone flaps that were replaced after freezing or far-site grafts harvested from patient calvarium, ribs, iliac crest [22,23]. Given the lower power of a test for heterogeneity, with only 2 studies of marginal sample sizes and poor quality, a random effects model was chosen. All analyses were tested at a 0.05 level of significance.

#### 3. Results

A total of 23 relevant studies were identified and screened. Ultimately, 15 studies were included in the meta-analysis (Fig. 1) [3,10,11,23,22,24-33]. Two studies addressed the association between complications and failure rates in patients who underwent cranioplasty with PEEK versus autologous implants, and 2 studies addressed the same association in patients who underwent cranioplasty with PEEK versus titanium implants [23,22,28,33]. The search yielded a total of 183 patients who underwent cranioplasty repair with PEEK (Table 1). Mean age was 38.1 years and 59% (n = 108) of patients were male. Mean length of surgery and length-of-stay were 3.27 h and 4.46 days, respectively (Table 2). Mean follow-up was 24.1 months. Post-operative complications were reported in 28 (15.3%) of patients. The most common complications of patients undergoing cranioplasty with PEEK were infection (6%), followed by hematoma formation (2.2%) and implant exposure (1.6%). Table 3 contains an exhaustive list of all complications of published cases of patients who underwent cranioplasty with PEEK. Sixteen patients (8.7%) experienced implant failure; 10 underwent implant removal and 6 underwent removal and revision.

#### 3.1. PEEK versus autologous bone graft

Two studies from the systematic review were included in the two meta-analyses comparing complication and failure rates of PEEK versus autologous bone graft cranioplasties. There was no significant difference in the complication rates of included and excluded studies ( $P(X^2 > 2.606) = 0.106$ ). The pooled odds ratio (OR) of complications after PEEK cranioplasty compared to autologous graft cranioplasty was 0.130 (95% CI: 0.014, 1.138; P = 0.065),





## **ARTICLE IN PRESS**

#### M. Punchak et al. / Journal of Clinical Neuroscience xxx (2017) xxx-xxx

#### Table 1

	Demographics data or	1 studies meeting criteria fo	or inclusion in systematic review.
--	----------------------	-------------------------------	------------------------------------

Citation	CEBM level of evidence	Country	Materials (N)	Gender	Age (YEARS)	Follow-up (Mo)
Alonso-Rodriguez et al. 2015	4	Spain	PEEK	4M, 10F	42.7	28.6 (5-72)
Camarini et al. 2011	N/A	Brazil	PEEK	1M	47	18
Coulter et al. 2013	N/A	UK	PEEK	1F	45 yrs	12
Gilardino et al. 2015	3b	Canada	A (15); PEEK (12)	A (11M,4F); PEEK (8M, 4F)	A (10); PEEK (23.5)	12
Hanasono et al. 2009	4	US	PEEK	2M, 4F	59.8	9
Iaccarino et al. 2015	3b	Italy	A (31); HA (50); PMMA (13); PEEK (2)	A (24M, 7F); HA (35M, 15F); PMMA (8M, 5F); PEEK (1M, 1F)	-	72
Jalbert et al. 2014	4	France	PEEK	1M, 4F	49.6	-
Kim et al. 2009	4	US	PEEK	1M, 3F	19	16-20
Manrique et al. 2015	4	US	PEEK	4M, 2F	46 (±20.63)	48
Ng et al. 2014	3b	Singapore	Ti (5); Ti-AC (7); PEEK (12)	Ti (4M, 1F); Ti-AC (5M, 2F); PEEK (9M, 3F)	TI (43); Ti-AC(35); PEEK (43)	Ti (16); Ti-AC (13); PEEK (7)
O'Reilly et al. 2015	4	US	PEEK	12M, 7F	39.6 (15-81)	59 (24-106)
Rammos et al. 2015	4	US	PEEK	5M, 6F	46 (19–81)	6 (1-12)
Rosenthal et al. 2014	4	US, Israel, Singapore	PEEK	46M, 19F	35 (±14)	24 (±16)
Scolozzi et al. 2007	4	Switzerland	PEEK	1 M	42	12
Thien et al. 2014	3b	Singapore	PEEK (24); Ti (108)	PEEK (13M, 11F); Ti (72M, 36F)	PEEK (35 ± 16; Ti (43.5 ± 15.5)	PEEK (16.9 ± 14.4); T (43.1 ± 35.1)

A = autologous, PEEK = polyetheretherketone, HA = hydroxyapatite, PMMA = poly(methyl methacrylate), Ti = titanium, AC = acrylic, M = male, F = female.

#### Table 2

Summary data for patients w/PEEK cranioplasties.

Total number of patients183Mean follow-up, mo $(n = 176)$ 24.1Mean age, yrs $(n = 181)$ 38.1Duration of surgery, h $(n = 44)$ 3.27Length of hospitalization, days $(n = 120)$ 4.46Gender $(n = 183)$ 108 (59.0%)Female $(%)$ 76 (41.5%)Indications for craniectomy $(n = 183)$ 9 (54.1%)Trauma $(%)$ 99 (54.1%)Tumor $(%)$ 34 (34.3%)Vascular $(%)$ 22 (12.0%)Congenital anomaly $(%)$ 11 (6.0%)Infection $(%)$ 11 (6.0%)Infection $(%)$ 18 (24.3%)Parietal $(%)$ 10 (13.5%)Temporal $(%)$ 8 (10.8%)Temporal $(%)$ 6 (8.1%)Fronto-orbital $(%)$ 6 (8.1%)Zygomaticomaxillary $(%)$ 5 (6.7%)Orbitomaxillary $(%)$ 2 (2.7%)Cocipitoparietal $(%)$ 1 (1.4%)Parietal $(%)$ 1 (1.4%)Printal $(%)$ 1 (1.4%)	summary auta for patients w/r ben cramophasticsr	
Mean age, yrs $(n = 181)$ 38.1Duration of surgery, h $(n = 44)$ 3.27Length of hospitalization, days $(n = 120)$ 4.46Gender $(n = 183)$ 108 $(59.0\%)$ Male $(%)$ 76 $(41.5\%)$ Indications for craniectomy $(n = 183)$ 76 $(41.5\%)$ Indications for craniectomy $(n = 183)$ 99 $(54.1\%)$ Tumor $(%)$ 34 $(34.3\%)$ Vascular $(%)$ 22 $(12.0\%)$ Congenital anomaly $(%)$ 11 $(6.0\%)$ Infection $(%)$ 11 $(6.0\%)$ Infection $(%)$ 18 $(24.3\%)$ Parietal $(%)$ 99 $(12.2\%)$ Frontal $(%)$ 90 $(12.2\%)$ Frontoparietal $(%)$ 6 $(8.1\%)$ Temporal $(%)$ 2 $(2.7\%)$ Orbital $(\%)$ 2 $(2.7\%)$ Orbital $(\%)$ 1 $(1.4\%)$ Parietal $(\%)$ 1 $(1.4\%)$ Parietal $(\%)$ 1 $(1.4\%)$ Pronto-orbital $(\%)$ 1 $(1.4\%)$ Prieto-occipital $(\%)$ 1 $(1.4\%)$ Parieto-occipital $(\%)$ 1 $(1.4\%)$	Total number of patients	183
Duration of surgery, h $(n = 44)$ 3.27Length of hospitalization, days $(n = 120)$ 4.46Gender $(n = 183)$ 108 (59.0%)Male $(%)$ 76 (41.5%)Indications for craniectomy $(n = 183)$ 76 (41.5%)Indications for craniectomy $(n = 183)$ 99 (54.1%)Trauma $(%)$ 99 (54.1%)Tumor $(%)$ 34 (34.3%)Vascular $(%)$ 22 (12.0%)Congenital anomaly $(%)$ 11 (6.0%)Infection $(%)$ 11 (6.0%)Infection $(%)$ 6 (3.3%)Location of defect $(n = 74)$ 18 (24.3%)Frontal $(%)$ 9 (12.2%)Frontoparietal $(%)$ 6 (8.1%)Temporal $(%)$ 6 (8.1%)Temporal $(%)$ 6 (8.1%)Zygomaticomaxillary $(%)$ 5 (6.7%)Orbital $(%)$ 2 (2.7%)Occipital $(%)$ 1 (1.4%)Parieto-occipital $(%)$ 1 (1.4%)Parieto-occipital $(%)$ 1 (1.4%)	Mean follow-up, mo $(n = 176)$	24.1
Length of hospitalization, days $(n = 120)$ 4.46Gender $(n = 183)$ 108 (59.0%)Male $(%)$ 108 (59.0%)Female $(\%)$ 76 (41.5%)Indications for craniectomy $(n = 183)$ 71 (41.5%)Indications for craniectomy $(n = 183)$ 99 (54.1%)Trauma $(\%)$ 99 (54.1%)Tumor $(\%)$ 34 (34.3%)Vascular $(\%)$ 22 (12.0%)Congenital anomaly $(\%)$ 11 (6.0%)Infection $(\%)$ 11 (6.0%)Infection $(\%)$ 11 (6%)Ischemic stroke $(\%)$ 6 (3.3%)Location of defect $(n = 74)$ 18 (24.3%)Parietal $(\%)$ 10 (13.5%)Temporal $(\%)$ 9 (12.2%)Frontoparietal $(\%)$ 6 (8.1%)Temporoparietal $(\%)$ 6 (8.1%)Temporoparietal $(\%)$ 6 (8.1%)Zygomaticomaxillary $(\%)$ 5 (6.7%)Orbital $(\%)$ 2 (2.7%)Occipitoparietal $(\%)$ 1 (1.4%)Parieto-occipital $(\%)$ 1 (1.4%)Parieto-occipital $(\%)$ 1 (1.4%)Parieto-occipital $(\%)$ 1 (1.4%)	Mean age, yrs $(n = 181)$	38.1
Gender $(n = 183)$ Male $(%)$ 108 $(59.0\%)$ Female $(%)$ 76 $(41.5\%)$ Indications for craniectomy $(n = 183)$ 76 $(41.5\%)$ Trauma $(%)$ 99 $(54.1\%)$ Tumor $(%)$ 34 $(34.3\%)$ Vascular $(%)$ 22 $(12.0\%)$ Congenital anomaly $(%)$ 11 $(6.0\%)$ Infection $(\%)$ 18 $(24.3\%)$ Porietal $(\%)$ 10 $(13.5\%)$ Temporal $(\%)$ 9 $(12.2\%)$ Frontal $(\%)$ 9 $(12.2\%)$ Frontoparietal $(\%)$ 6 $(8.1\%)$ Temporal $(\%)$ 6 $(8.1\%)$ Temporal $(\%)$ 6 $(8.1\%)$ Zygomaticomaxillary $(\%)$ 5 $(6.7\%)$ Orbital $(\%)$ 2 $(2.7\%)$ Occipitoparietal $(\%)$ 1 $(1.4\%)$ Parieto-occipital $(\%)$ 1 $(1.4\%)$ Parieto-occipital $(\%)$ 1 $(1.4\%)$	Duration of surgery, $h(n = 44)$	3.27
Male $(%)$ 108 (59.0%)Female $(%)$ 76 (41.5%)Indications for craniectomy ( $n = 183$ )76 (41.5%)Trauma $(%)$ 99 (54.1%)Tumor $(%)$ 34 (34.3%)Vascular $(%)$ 22 (12.0%)Congenital anomaly $(%)$ 11 (6.0%)Infection $(%)$ 11 (6.0%)Infection $(%)$ 6 (3.3%)Location of defect ( $n = 74$ )18 (24.3%)Parietal $(%)$ 10 (13.5%)Temporal $(%)$ 9 (12.2%)Frontoparietal $(%)$ 6 (8.1%)Temporal $(%)$ 6 (8.1%)Fronto-orbital $(%)$ 6 (8.1%)Zygomaticomaxillary $(%)$ 5 (6.7%)Orbitomaxillary $(%)$ 2 (2.7%)Occipitoparietal $(%)$ 1 (1.4%)Parieto-occipital $(%)$ 1 (1.4%)Parieto-occipital $(%)$ 1 (1.4%)	Length of hospitalization, days $(n = 120)$	4.46
Female (%)76 (41.5%)Indications for craniectomy ( $n = 183$ )76 (41.5%)Trauma (%)99 (54.1%)Tumor (%)34 (34.3%)Vascular (%)22 (12.0%)Congenital anomaly (%)11 (6.0%)Infection (%)11 (6.0%)Infection (%)6 (3.3%)Location of defect ( $n = 74$ )Frontal (%)10 (13.5%)Temporal (%)9 (12.2%)Frontoparietal (%)6 (8.1%)Temporal (%)6 (8.1%)Zygomaticomaxillary (%)6 (8.1%)Zygomaticomaxillary (%)2 (2.7%)Orbitral (%)1 (1.4%)Parietal (%)1 (1.4%)Orbitofrontotemporal (%)1 (1.4%)	Gender ( <i>n</i> = 183)	
Indications for craniectomy $(n = 183)$ 99 (54.1%)   Trauma (%) 99 (54.1%)   Tumor (%) 34 (34.3%)   Vascular (%) 22 (12.0%)   Congenital anomaly (%) 11 (6.0%)   Infection (%) 11 (6.%)   Ischemic stroke (%) 6 (3.3%)   Location of defect ( $n = 74$ ) 7   Frontal (%) 10 (13.5%)   Parietal (%) 9 (12.2%)   Frontoparietal (%) 6 (8.1%)   Temporal (%) 9 (12.2%)   Frontoparietal (%) 6 (8.1%)   Zygomaticomaxillary (%) 6 (8.1%)   Zygomaticomaxillary (%) 2 (2.7%)   Orbital (%) 2 (2.7%)   Temporal-parietal-occipital (%) 1 (1.4%)   Parieto-occipital (%) 1 (1.4%)	Male (%)	108 (59.0%)
Trauma (%)99 (54.1%)Tumor (%)34 (34.3%)Vascular (%)22 (12.0%)Congenital anomaly (%)11 (6.0%)Infection (%)11 (6.0%)Infection (%)11 (6.0%)Ischemic stroke (%)6 (3.3%)Location of defect ( $n = 74$ )8 (24.3%)Frontal (%)9 (12.2%)Frontoparietal (%)6 (8.1%)Temporal (%)6 (8.1%)Fronto-orbital (%)6 (8.1%)Zygomaticomaxillary (%)5 (6.7%)Orbital (%)2 (2.7%)Occipitoparietal (%)1 (1.4%)Parieto-occipital (%)1 (1.4%)Orbitofrontotemporal (%)1 (1.4%)	Female (%)	76 (41.5%)
Tumor (%) $34$ (34.3%)Vascular (%) $22$ (12.0%)Congenital anomaly (%) $11$ (6.0%)Infection (%) $11$ (6.0%)Ischemic stroke (%) $6$ (3.3%)Location of defect ( $n = 74$ )Frontal (%) $10$ (13.5%)Parietal (%) $10$ (13.5%)Temporal (%) $9$ (12.2%)Fronto-orbital (%) $6$ (8.1%)Tronto-orbital (%) $6$ (8.1%)Zygomaticomaxillary (%) $5$ (6.7%)Orbitomaxillary (%) $2$ (2.7%)Occipitoparietal (%) $1$ (1.4%)Parieto-occipital (%) $1$ (1.4%)	Indications for craniectomy $(n = 183)$	
Vascular (%)22 (12.0%)Congenital anomaly (%)11 (6.0%)Infection (%)11 (6.0%)Ischemic stroke (%)6 (3.3%)Location of defect ( $n = 74$ )Frontal (%)18 (24.3%)Parietal (%)10 (13.5%)Temporal (%)9 (12.2%)Frontoparietal (%)6 (8.1%)Temporoparietal (%)6 (8.1%)Zygomaticomaxillary (%)5 (6.7%)Orbital (%)2 (2.7%)Occipitoparietal (%)1 (1.4%)Parieto-occipital (%)1 (1.4%)Orbitofrontotemporal (%)1 (1.4%)	Trauma (%)	99 (54.1%)
Congenital anomaly (%)11 (6.0%)Infection (%)11 (6%)Ischemic stroke (%)6 (3.3%)Location of defect ( $n = 74$ )6 (3.3%)Frontal (%)18 (24.3%)Parietal (%)10 (13.5%)Temporal (%)9 (12.2%)Frontoparietal (%)6 (8.1%)Temporoparietal (%)6 (8.1%)Temporoparietal (%)6 (8.1%)Vygomaticomaxillary (%)5 (6.7%)Orbital (%)2 (2.7%)Occipitoparietal (%)1 (1.4%)Parieto-occipital (%)1 (1.4%)Orbitofrontotemporal (%)1 (1.4%)	Tumor (%)	34 (34.3%)
Infection (%) 11 (6%)   Ischemic stroke (%) 6 (3.3%)   Location of defect ( $n = 74$ ) 7   Frontal (%) 18 (24.3%)   Parietal (%) 10 (13.5%)   Temporal (%) 9 (12.2%)   Frontoparietal (%) 8 (10.8%)   Temporaparietal (%) 6 (8.1%)   Fronto-orbital (%) 6 (8.1%)   Zygomaticomaxillary (%) 5 (6.7%)   Orbital (%) 4 (5.4%)   Orbitomaxillary (%) 2 (2.7%)   Occipitoparietal (%) 1 (1.4%)   Parieto-occipital (%) 1 (1.4%)   Orbitofrontotemporal (%) 1 (1.4%)	Vascular (%)	22 (12.0%)
Ischemic stroke (%)   6 (3.3%)     Location of defect (n = 74)   18 (24.3%)     Frontal (%)   10 (13.5%)     Parietal (%)   10 (13.5%)     Temporal (%)   9 (12.2%)     Frontoparietal (%)   8 (10.8%)     Temporoparietal (%)   6 (8.1%)     Zygomaticomaxillary (%)   6 (8.1%)     Orbital (%)   4 (5.4%)     Orbitmaxillary (%)   2 (2.7%)     Occipitoparietal (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)	Congenital anomaly (%)	11 (6.0%)
Location of defect $(n = 74)$ 18 (24.3%)     Frontal $(\%)$ 10 (13.5%)     Parietal $(\%)$ 9 (12.2%)     Frontoparietal $(\%)$ 9 (12.2%)     Frontoparietal $(\%)$ 6 (8.1%)     Temporoparietal $(\%)$ 6 (8.1%)     Toroto-orbital $(\%)$ 6 (8.1%)     Zygomaticomaxillary $(\%)$ 5 (6.7%)     Orbital $(\%)$ 2 (2.7%)     Occipitoparietal $(\%)$ 2 (2.7%)     Temporal-parietal-occipital $(\%)$ 1 (1.4%)     Parieto-occipital $(\%)$ 1 (1.4%)     Orbitofrontotemporal $(\%)$ 1 (1.4%)	Infection (%)	11 (6%)
Frontal (%) 18 (24.3%)   Parietal (%) 10 (13.5%)   Temporal (%) 9 (12.2%)   Frontoparietal (%) 8 (10.8%)   Temporoparietal (%) 6 (8.1%)   Fronto-orbital (%) 6 (8.1%)   Zygomaticomaxillary (%) 5 (6.7%)   Orbital (%) 4 (5.4%)   Orbitomaxillary (%) 2 (2.7%)   Occipitoparietal (%) 1 (1.4%)   Parieto-occipital (%) 1 (1.4%)   Orbitofrontotemporal (%) 1 (1.4%)	Ischemic stroke (%)	6 (3.3%)
Parietal (%) 10 (13.5%)   Temporal (%) 9 (12.2%)   Frontoparietal (%) 8 (10.8%)   Temporoparietal (%) 6 (8.1%)   Temporoparietal (%) 6 (8.1%)   Fronto-orbital (%) 6 (8.1%)   Zygomaticomaxillary (%) 5 (6.7%)   Orbital (%) 2 (2.7%)   Occipitoparietal (%) 2 (2.7%)   Temporal-parietal-occipital (%) 1 (1.4%)   Parieto-occipital (%) 1 (1.4%)   Orbitofrontotemporal (%) 1 (1.4%)	Location of defect $(n = 74)$	
Temporal (%) 9 (12.2%)   Frontoparietal (%) 8 (10.8%)   Temporoparietal (%) 6 (8.1%)   Fronto-orbital (%) 6 (8.1%)   Zygomaticomaxillary (%) 5 (6.7%)   Orbital (%) 4 (5.4%)   Orbitomaxillary (%) 2 (2.7%)   Occipitoparietal (%) 1 (1.4%)   Parieto-occipital (%) 1 (1.4%)   Orbitofrontotemporal (%) 1 (1.4%)	Frontal (%)	18 (24.3%)
Frontoparietal (%)   8 (10.8%)     Temporoparietal (%)   6 (8.1%)     Fronto-orbital (%)   6 (8.1%)     Zygomaticomaxillary (%)   5 (6.7%)     Orbital (%)   4 (5.4%)     Orbitomaxillary (%)   2 (2.7%)     Occipitoparietal (%)   2 (2.7%)     Temporal-parietal-occipital (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)	Parietal (%)	10 (13.5%)
Temporoparietal (%)   6 (8.1%)     Fronto-orbital (%)   6 (8.1%)     Zygomaticomaxillary (%)   5 (6.7%)     Orbital (%)   4 (5.4%)     Orbital (%)   2 (2.7%)     Occipitoparietal (%)   2 (2.7%)     Temporal-parietal-occipital (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)	Temporal (%)	9 (12.2%)
Fronto-orbital (%)   6 (8.1%)     Zygomaticomaxillary (%)   5 (6.7%)     Orbital (%)   4 (5.4%)     Orbital (%)   2 (2.7%)     Occipitoparietal (%)   2 (2.7%)     Temporal-parietal-occipital (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)	Frontoparietal (%)	8 (10.8%)
Zygomaticomaxillary (%)   5 (6.7%)     Orbital (%)   4 (5.4%)     Orbitomaxillary (%)   2 (2.7%)     Occipitoparietal (%)   2 (2.7%)     Temporal-parietal-occipital (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)		6 (8.1%)
Orbital (%)   4 (5.4%)     Orbitomaxillary (%)   2 (2.7%)     Occipitoparietal (%)   2 (2.7%)     Temporal-parietal-occipital (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)	Fronto-orbital (%)	6 (8.1%)
Orbitomaxillary (%)   2 (2.7%)     Occipitoparietal (%)   2 (2.7%)     Temporal-parietal-occipital (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)	Zygomaticomaxillary (%)	5 (6.7%)
Occipitoparietal (%)   2 (2.7%)     Temporal-parietal-occipital (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)	Orbital (%)	4 (5.4%)
Temporal-parietal-occipital (%)   1 (1.4%)     Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)	Orbitomaxillary (%)	2 (2.7%)
Parieto-occipital (%)   1 (1.4%)     Orbitofrontotemporal (%)   1 (1.4%)	Occipitoparietal (%)	2 (2.7%)
Orbitofrontotemporal (%) 1 (1.4%)		· · ·
		· · ·
Occipital (%) 1 (1.4%)		· · ·
	Occipital (%)	1 (1.4%)

representing a 7.69-fold increase in the odds of developing postoperative complications following autologous cranioplasty compared to PEEK cranioplasty (Fig. 2). None of the 24 PEEK cranioplasties failed, while five of the 46 autologous grafts failed during the 12-month follow-up period (Fig. 3). The pooled OR of implant failure after PEEK cranioplasty compared to autologous graft cranioplasty was 0.574 (95% CI: 0.061, 5.448; P = 0.629), representing a 1.74-fold increase in odds of experiencing implant failure with an autologous graft.

Table 3				
PEEK cranioplasty outcomes	s (n	=	183)	•

Outcome	N (%)
Infection	11 (6.0)
Hematoma	4 (2.2)
Implant Exposure	3 (1.6)
Seroma	2(1.1)
Wound Breakdown	2 (1.1)
New Seizures	2 (1.1)
CSF Leak	2 (1.1)
Post-Op Edema	2 (1.1)
Total Complication Implant Failure	28 (15.3) 16 (8.7)

#### 3.2. PEEK versus titanium mesh

Two studies from the systematic review were included in the two meta-analyses comparing complication and failure rates of PEEK versus titanium graft cranioplasties. There was no significant difference in the complication rates of included and excluded studies  $(P(X^2 > 0.073) = 0.787)$ . The pooled OR of complications after PEEK cranioplasty compared to titanium cranioplasty was 0.127 (95% CI: 0.002, 8.864; *P* = 0.360), representing a 7.87-fold increase in odds of developing post-operative complications after titanium mesh cranioplasty compared to PEEK cranioplasty (Fig. 4). Three out of a total of 36 PEEK cranioplasties failed, while 33 of the 113 titanium cranioplasties failed during the follow-up period of at least 6 months (Fig. 5). The pooled OR of implant failure after PEEK cranioplasty compared to titanium cranioplasty was 0.170 (95% CI: 0.014, 2.110; P = 0.168). Inversely, this represents a 5.88fold increase in odds of failure following titanium mesh cranioplasty compared to PEEK cranioplasty.

#### 4. Discussion

Cranial reconstruction is a procedure generally performed with either autologous or alloplastic materials. An increasingly popular variation of the latter is the PEEK implant, with several advantages

## **ARTICLE IN PRESS**

#### M. Punchak et al./Journal of Clinical Neuroscience xxx (2017) xxx-xxx

Figure 2. Forest plot showing meta-ana	lysis of 2 studies comparing	complication rates with PEEK vs. au	tologous graft cranioplasties

Complications			Odds Ratio	Odds Ratio	
Study	PEEK (n, %)	Autologous (n, %)	Weight	M-H Fixed (95% CI)	M-H Fixed (95% CI)
Gilardino et al. 2015	0/12 (0%)	7/15 (46.7%)	52.14%	0.045 (0.002, 0.904)	←
Iaccarino et al. 2015	0/2 (0%)	10/31 (32.%)	47.86%	0.410 (0.18, 9.318)	
Total (95% CI)	24	46		0.130 (0.014, 1.138)	
Total events	0	17			.d1 .h 10
Heterogeneity: Tau2=0.0	0204; Chi2=1.01, df=	1 (P=0.315)			
Test for overall effect: 2	Z=1.84 (P=0.065)				

CI=confidence interval

Fig. 2. Forest plot showing meta-analysis of 2 studies comparing complication rates with PEEK vs. autologous graft cranioplasties.

#### Figure 3. Forest plot showing meta-analysis of 2 studies comparing failure rates with PEEK vs. autologous graft cranioplasties

	]	Failure		<b>Odds Ratio</b>	Odds Ratio
Study	<b>PEEK (n, %)</b>	Autologous (n, %)	Weight	M-H Fixed (95% CI)	M-H Fixed (95% CI)
Gilardino et al. 2015	0/12 (0%)	2/15 (13.3%)	51.58%	0.216 (0.009, 4.952)	
Iaccarino et al. 2015	0/2 (0%)	3/31 (9.7%)	48.42%	1.629 (0.064, 41.290)	
Total (95% CI)	14	46		0.574 (0.061, 5.448)	
Total events	0	5			.01 .1 1 10
Heterogeneity: Tau2=0.0	000; Chi2=0.80, df	=1 (P=0.372)			
Test for overall effect:	Z=0.48 (P=0.629)				

CI=confidence interval

Fig. 3. Forest plot showing meta-analysis of 2 studies comparing failure rates with PEEK vs. autologous graft cranioplasties.

### Figure 4. Forest plot showing meta-analysis of 2 studies comparing complication rates with PEEK vs. titanium cranioplasties

	Com	olications		<b>Odds Ratio</b>	Odds Ratio
Study	PEEK (n, %)	Titanium (n, %)	Weight	M-H Random (95% CI)	M-H Random (95% CI)
Ng et al. 2014	0/12 (0%)	4/5 (80.0%)	42.45%	0.013 (0.0004, 0.390)	
Thien et al. 2014	6/24 (25.0%)	30/108 (27.8%)	57.55%	0.867 (0.314, 2.392)	
Total (95% CI)	36	113		0.127 (0.002, 8.864)	
Total events	6	34			.01 .1 1 10
Heterogeneity: Tau2=	=7.32; Chi2=5.53, d	f=1 (P=0.019)			
Test for overall effe	ct: Z=0.92 (P=0.36	0)			

CI=confidence interval

Fig. 4. Forest plot showing meta-analysis of 2 studies comparing complication rates with PEEK vs. titanium cranioplasties.

#### Figure 5. Forest plot showing meta-analysis of 2 studies comparing failure rates with PEEK vs. titanium cranioplasties

	F٤	ailure		<b>Odds Ratio</b>	<b>Odds Ratio</b>
Study	<b>PEEK (n, %)</b>	Titanium (n, %)	Weight	M-H Fixed( 95% CI)	M-H Random (95% CI)
Ng et al. 2014	0/12 (0%)	3/5 (60.0%)	34.09%	0.029 (0.001, 0.744)	<
Thien et al. 2014	3/24 (12.5%)	27/108 (25.0%)	65.91%	0.429 (0.118, 1.550)	
Total (95% CI)	36	113		0.170 (0.014, 2.110)	
Total events	3	30			
Heterogeneity: Tau2=	=2.07; Chi2=2.30, df	=1 (P=0.130)			
Test for overall effect	ct: Z=1.38 (P=0.168	5)			

CI=confidence interval

Fig. 5. Forest plot showing meta-analysis of 2 studies comparing failure rates with PEEK vs. titanium cranioplasties.

associated with its use. Despite its increasing acceptance, however, there is a paucity of literature on the efficacy and side-effect profile of PEEK relative to other common cranioplasty techniques. To date, this is the first meta-analysis that compares outcomes of cranial vault reconstruction using PEEK, autologous bone graft, and titanium implant.

Our initial search yielded a relatively low number of available studies on outcomes of PEEK cranioplasty, and even fewer studies with comparison of PEEK to other reconstruction materials. Having said that, the literature demonstrates a steady increase in the number of publications on this topic over the past several years. While only a single case report was published in 2007, ten manuscripts were published in the past two years, including six case series and four retrospective cohorts.

A third of all studies included in our meta-analysis were carried out by institutions in the United States. Other countries represented included Singapore, Israel, France, Spain, Italy, Switzerland, Canada and Brazil. While country appears to be a strong confounder, subgroup analysis of country and outcomes was statistically infeasible. Other putative confounders such as patient population, use of antibiotics, year of procedure, time to craniectomy should be explored in future studies.

Given the dearth of literature on PEEK cranioplasty outcomes and the growing interest in the use of this material in neurosurgical and craniofacial reconstruction, our meta-analysis focused on determining how PEEK cranioplasties fare relative to other more established materials, specifically autologous bone grafts and titanium mesh implants. The authors of this study identified a 15.3% complication rate for PEEK cranioplasties, including infection, hematoma formation and implant exposure. Current literature reports comparable complication rates for cranioplasties when alternative materials are used. In fact, studies have shown a complication rate of 13.3–46.7% when autologous bone implants are used in cranioplasty and 0–58.3% when titanium mesh implants are used in cranioplasty [8,23,22,28,33–41].

Our meta-analyses did not reveal a significant difference in complication rates between PEEK and autologous bone graft or titanium graft cranioplasties. However, there was a trend toward decreased post-operative complication rates of PEEK cranioplasties compared to autologous grafts. Given that only two studies comparing outcomes were included in each of the meta-analyses, it is possible if more studies were available for inclusion, a significant difference would have been observed.

Implant infection was the most commonly observed complication among patients in this study, with 11% of the 183 patients undergoing a PEEK cranioplasty developing a post-operative infection. Reported autologous graft infection rates have ranged between 0% and 25.9% in literature, while titanium mesh implant infection rates have been reported to be lower, ranging between 0% and 11% [7,23,22,28,33,35]. Because of the small number of published studies on this topic and the limited number of patients included these studies, it was not statistically feasible to compare infection rates associated with the various materials used for cranioplasty.

Implant failure is the most serious potential adverse event associated with cranioplasty as it uniformly requires removal of the graft and reoperation using either far-site autologous grafts or synthetic material for reconstruction. Far-site autografts lead to donor-site morbidity and worse cosmetic outcomes, while synthetic materials are more costly and lead to problems with tissue compatibility [42]. In our meta-analysis, we noted a 8.7% failure rate of PEEK cranioplasties. In the current literature, reported autograft failure rates have ranged from 9.8% to 31%. Comparing these rates to those reported in our analysis, PEEK implants may fail less frequently [23,22,35]. Failure rates of titanium mesh implants have ranged from 0% to 50%, placing failure rate of PEEK cranioplasties observed in our data within the reported range [28,33,35].

We did not observe a significant difference in failure rates between either PEEK and autologous grafts or PEEK and titanium grafts in our meta-analysis. However, compared to PEEK versus autologous graft analyses, there was stronger trend toward lower failure rates of PEEK grafts compared to titanium grafts. One major difference between autologous bone and titanium mesh is variances in post-operative complications. Implant exposure was a more commonly observed complication of titanium implants than infection in the two studies that were eligible for inclusion in the pooled analysis, while infection rates were higher in autologous grafts [28,33]. Implant extrusion is a common indication for reoperation following titanium implant based cranioplasty. However, infection may be treated non-operatively in the initial period in an attempt to preserve the graft and avoid risks associated with reoperation.

#### 4.1. Limitations

Several limitations were encountered in this study. The paucity of published studies led to a small sample size, and thus, low statistical power which could have resulted in an overestimation of the effect size. Several of the studies included in this analysis collected data in retrospective fashion, increasing the likelihood for selection and reporting biases. The follow-up period varied across studies between 6 months and almost 5 years, which may have led to an underestimation in the incidence of our outcomes of interest. Of great importance is that the authors did not adjudicate the quality of the studies examined in the meta-analysis. It was understood that the individual studies (specifically, retrospective cohorts) are predisposed to selection and publication biases; however, given the small number of studies identified further assessment of risk of bias would not have contributed significantly to the analysis. The meta-analysis predominantly consists of various pair-wise, non-randomized comparisons as opposed to examining multiple cranioplasty types, which limits interpretation of the results. Finally, given the small number of studies included in the metaanalysis, prior cranioplasty, age or location of cranioplasty, history of prior infection, and size of implant (all known factors predicting failure) could not be controlled for. Therefore, a random-effects model was chosen for the meta-analysis.

#### 5. Conclusions

PEEK implants have been less studied in the context of their recent introduction to neurosurgical practice. The study herein presented is the first to aggregate all currently published data on outcomes of patients undergoing cranioplasty with PEEK, and to compare outcomes in patients undergoing cranioplasty with PEEK compared to autologous and titanium grafts. There was a trend toward lower post-operative complication rates after PEEK cranioplasties compared to autologous cranioplasties. Patients undergoing PEEK and titanium mesh cranioplasties, demonstrated a trend toward lower failure rates of PEEK versus titanium mesh implants. Differences in complication rates and failure rates failed to achieve statistical significance. Synthesis of the data was severely limited by the paucity of literature and low-quality of the studies analyzed. This study qualifies as a preliminary analysis that begins to address the knowledge gap in determining the complication and failure rates in cranioplasty procedures. However, future investigations involving greater numbers of comparative studies are necessary to validate the superiority of one material/technique over others.

6

M. Punchak et al. / Journal of Clinical Neuroscience xxx (2017) xxx-xxx

#### Conflicts of interest/disclosures

Lawrance K. Chung was partially supported by an AMA Foundation Seed Grant, an A $\Omega$ A Carolyn L. Kuckein Student Research Fellowship and a Gurtin Skull Base Research Fellowship. Carlito Lagman was partially supported by a Gurtin Skull Base Research Fellowship. Isaac Yang (senior author) was partially supported by a Visionary Fund Grant, an Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research UCLA Scholars in Translational Medicine Program Award, the Jason Dessel Memorial Seed Grant, the UCLA Honberger Endowment Brain Tumor Research Seed Grant, and the Stop Cancer (US) Research Career Development Award. The authors have no personal or institutional conflicts of interest, specifically those relating to polyetheretherketone (PEEK) implants or companies involved in the production of PEEK implants.

#### References

- Grant F, Norcross NC. Repair of cranial defects by cranioplasty. Ann Surg 1939;110:488–512.
- [2] Feroze AH, Walmsley GG, Choudhri O, et al. Evolution of cranioplasty techniques in neurosurgery: historical review, pediatric considerations, and current trends. J Neurosurg 2015;123:1–10.
- [3] Alonso-Rodriguez E, Cebrián JL, Nieto MJ, et al. Polyetheretherketone custommade implants for craniofacial defects: Report of 14 cases and review of the literature. J Cranio-Maxillofacial Surg 2015;43:1232–8.
- [4] Shah AM, Jung H, Skirboll S. Materials used in cranioplasty: a history and analysis. Neurosurg Focus 2014;36:E19.
- [5] Engstrand J, Persson C, Engqvist H. Influence of polymer addition on the mechanical properties of a premixed calcium phosphate cement. Biomatter 2013:1–7.
- [6] Laurencin CT, Ambrosio AMA, Borden MD, et al. Tissue engineering: orthopedic applications. Annu Rev Biomed Eng 1999;1:19–46.
- [7] Matsuno A, Tanaka H, Iwamuro H, et al. Analyses of the factors influencing bone graft infection after delayed cranioplasty. Acta Neurochir (Wien) 2006;148:535–40.
- [8] Wiggins A, Austerberry R, Morrison D, et al. Cranioplasty with custom-made titanium plates–14 years experience. Neurosurgery 2013;72.
- [9] Eseonu CI, Goodwin CR, Zhou X, et al. HHS Public Access. J Neurosurg 2016;123:1476–9.
- [10] Hanasono MM, Goel N, DeMonte F. Calvarial reconstruction with polyetheretherketone implants. Ann Plast Surg 2009;62:653–5.
- [11] Camarini ET, Tomeh JK, Dias RR, et al. Reconstruction of frontal bone using specific implant polyether-ether-ketone. J Craniofac Surg 2011;22:2205–7.
- [12] Lethaus B, Bloebaum M, Essers B, et al. Patient-specific implants compared with stored bone grafts for patients with interval cranioplasty. J Craniofac Surg 2014;25:206–9.
- [13] Lethaus B, Bloebaum M, Koper D, et al. Interval cranioplasty with patientspecific implants and autogenous bone grafts – success and cost analysis. J Cranio-Maxillofacial Surg 2014;42:1948–51.
- [14] Honeybul S, Ho KM. Cranioplasty: morbidity and failure. Br J Neurosurg 2016;8697:1-6.
- [15] Liang ES, Tipper G, Hunt L, et al. Cranioplasty outcomes and associated complications: a single-centre observational study. Br J Neurosurg 2015;8697:1–6.
- [16] De Bonis P, Frassanito P, Mangiola A, et al. Cranial repair: how complicated is filling a "hole"? J Neurotrauma 2012;29:1071–6.
- [17] Goodson ML, Farr D, Keith D, et al. Use of two-piece polyetheretherketone (PEEK) implants in orbitozygomatic reconstruction. Br J Oral Maxillofac Surg 2012;50:268–9.
- [18] Piitulainen JM, Kauko T, Aitasalo KMJ, et al. Outcomes of cranioplasty with synthetic materials and autologous bone grafts. World Neurosurg 2015;83:708–14.

- [19] Merola J, Muthu T, Hussain Z, et al. Case report: destructive neuroendocrine cranial tumour and the role of pre-fashioned polyetheretherketone (PEEK) cranioplasty. Open Cancer J 2012;5:7–10.
- [20] Nazimi AJ, Md Yusoff M, Nordin R, et al. Use of polyetheretherketone (PEEK) in orbital floor fracture reconstruction – a case for concern. J Oral Maxillofac Surgery Med Pathol 2015;27:536–9.
- [21] Ng ZY, Nawaz I. Computer-designed PEEK implants. J Craniofac Surg 2014;25: e55–88.
- [22] Gilardino MS, Karunanayake M, Al-Humsi T, et al. A comparison and cost analysis of cranioplasty techniques. J Craniofac Surg 2015;26:113–7.
- [23] Iaccarino C, Viaroli E, Fricia M, et al. Preliminary results of a prospective study on methods of cranial reconstruction. J Oral Maxillofac Surg 2015;73:2375–8.
- [24] Coulter C, Richards R, Peterson D, et al. Parietal skull reconstruction using immediate peek cranioplasty following resection for craniofacial fibrous dysplasia. J Plast Reconstr Aesthetic Surg 2014;67:e208–9.
- [25] Jalbert F, Boetto S, Nadon F, et al. One-step primary reconstruction for complex craniofacial resection with PEEK custom-made implants. J Cranio-Maxillofacial Surg 2014;42:141–8.
- [26] Kim MM, Boahene KDO, Byrne PJ. Use of customized polyetheretherketone (PEEK) implants in the reconstruction of complex maxillofacial defects. Arch Facial Plast Surg Off Publ Am Acad Facial Plast Reconstr Surgery Inc Int Fed Facial Plast Surg Soc 2009;11:53–7.
- [27] Manrique OJ, Lalezarzadeh F, Dayan E, et al. Craniofacial reconstruction using patient-specific implants polyether ether ketone with computer-assisted planning. J Craniofac Surg 2015;26:663–6.
- [28] Ng ZY, Ang WJJ, Nawaz I. Computer-designed polyetheretherketone implants versus titanium mesh (±acrylic cement) in alloplastic cranioplasty. J Craniofac Surg 2014;25:e185–9.
- [29] O'Reilly EB, Barnett S, Madden C, et al. Computed-tomography modeled polyether ether ketone (PEEK) implants in revision cranioplasty. J Plast Reconstr Aesthetic Surg 2015;68:329–38.
- [30] Rammos CK, Cayci C, Castro-Garcia JA, et al. Patient-specific polyetheretherketone implants for repair of craniofacial defects. J Craniofac Surg 2015;26:631–3.
- [31] Rosenthal G, Ng I, Moscovici S, et al. Polyetheretherketone implants for the repair of large cranial defects: a 3-center experience. Neurosurgery 2014;75:523–8.
- [32] Scolozzi P, Martinez A, Jaques B. Complex orbito-fronto-temporal reconstruction using computer-designed PEEK implant. J Craniofac Surg 2007;18:224–8.
- [33] Thien A, King NKK, Ang BT, et al. Comparison of polyetheretherketone and titanium cranioplasty after decompressive craniectomy. World Neurosurg 2015;83:176–80.
- [34] Crotti F, Mangiagalli E. Cranial defects repair by replacing bone flaps. J Neurosurg Sci 1979;23:289–94.
- [35] Honeybul S, Morrison DA, Ho KM, et al. A randomized controlled trial comparing autologous cranioplasty with custom-made titanium cranioplasty. J Neurosurg 2016:1–10.
- [36] Eufinger H, Saylor B. Computer-assisted prefabrication of individual craniofacial implants. AORN J 2001;74:648–54.
- [37] Gear AJL, Lokeh A, Aldridge JH, et al. Safety of titanium mesh for orbital reconstruction. Ann Plast Surg 2002;48:1–9.
- [38] Heissler E, Fischer F-S, Boiouri S, et al. Custom-made cast titanium implants produced with CAD/CAM for the reconstruction of cranium defects. Int J Oral Maxillofac Surg 1998;27:334–8.
- [39] Joffe J, Harris M, Kahugu F, et al. A prospective study of computer-aided design and manufacture of titanium plate for cranioplasty and its clinical outcome. Br J Neurosurg 1999;13:576–80.
- [40] Kuttenberger JJ, Hardt N. Long-term results following reconstruction of craniofacial defects with titanium micro-mesh systems. J Craniomaxillofacial Surg 2016;29:75–81.
- [41] Vahtsevanos K, Triaridis S, Patrikidou A, et al. The Atkinson Morley's Hospital joint neurosurgical – maxillofacial procedures: Cranioplasty case series 1985– 2003. J Craniomaxillofacial Surg 2007;35:336–42.
- [42] Sari R, Tonge M, Bolukbasi FH, et al. Management of failed cranioplasty. Turk Neurosurg 2015:1–7.